| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
24,964 |
22,726 |
$4.29M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
25,384 |
22,413 |
$4.00M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
29,388 |
25,180 |
$3.85M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
4,438 |
3,814 |
$1.52M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
26,456 |
22,686 |
$1.29M |
| 71045 |
Radiologic examination, chest; single view |
9,014 |
7,718 |
$1.28M |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
687 |
593 |
$1.23M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
18,303 |
15,469 |
$1.14M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
806 |
665 |
$696K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
9,551 |
9,067 |
$686K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
17,777 |
15,330 |
$632K |
| 71046 |
Radiologic examination, chest; 2 views |
6,353 |
5,608 |
$610K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
5,794 |
5,154 |
$470K |
| 62323 |
|
462 |
413 |
$378K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
867 |
376 |
$349K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,963 |
1,219 |
$325K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,118 |
2,595 |
$294K |
| 80053 |
Comprehensive metabolic panel |
42,662 |
36,246 |
$251K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
47,576 |
40,229 |
$204K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
134 |
107 |
$193K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
4,310 |
3,734 |
$181K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
7,844 |
7,448 |
$149K |
| 80320 |
|
1,448 |
1,307 |
$138K |
| 36415 |
Collection of venous blood by venipuncture |
33,815 |
28,333 |
$137K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,958 |
1,224 |
$134K |
| 87503 |
|
4,564 |
4,100 |
$110K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,695 |
1,472 |
$99K |
| 97597 |
|
656 |
403 |
$86K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,162 |
1,991 |
$84K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,092 |
1,846 |
$81K |
| 80050 |
General health panel |
664 |
558 |
$78K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,443 |
2,183 |
$67K |
| 84484 |
|
11,420 |
7,821 |
$62K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
11,581 |
9,728 |
$55K |
| 81025 |
|
9,826 |
8,339 |
$54K |
| 59025 |
Fetal non-stress test |
178 |
134 |
$47K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
269 |
223 |
$41K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,666 |
3,319 |
$41K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
624 |
375 |
$39K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
30 |
27 |
$38K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
631 |
539 |
$38K |
| 83690 |
|
11,444 |
9,926 |
$38K |
| 36591 |
|
716 |
448 |
$35K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
939 |
852 |
$29K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
910 |
826 |
$28K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
949 |
785 |
$28K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
145 |
111 |
$27K |
| 81001 |
|
13,243 |
11,516 |
$23K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
116 |
108 |
$23K |
| 29581 |
|
162 |
67 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,204 |
1,024 |
$21K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
646 |
580 |
$19K |
| 80329 |
|
324 |
173 |
$18K |
| 96367 |
|
479 |
289 |
$17K |
| 87276 |
|
1,827 |
1,506 |
$15K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
410 |
375 |
$14K |
| 84439 |
|
2,126 |
1,898 |
$14K |
| 80061 |
Lipid panel |
1,625 |
1,466 |
$13K |
| 87275 |
|
1,827 |
1,506 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,206 |
1,116 |
$13K |
| 83735 |
|
3,238 |
2,755 |
$12K |
| 81003 |
|
8,526 |
7,232 |
$12K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,256 |
1,969 |
$11K |
| 87536 |
|
158 |
142 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,773 |
1,583 |
$9K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
169 |
110 |
$8K |
| 86780 |
|
599 |
550 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,833 |
1,529 |
$7K |
| 83880 |
|
360 |
297 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
403 |
339 |
$6K |
| 74018 |
|
35 |
30 |
$6K |
| 80143 |
|
387 |
335 |
$5K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14 |
13 |
$5K |
| 85027 |
|
1,325 |
1,138 |
$5K |
| 83605 |
|
851 |
607 |
$5K |
| 88142 |
|
250 |
226 |
$4K |
| 29580 |
|
33 |
12 |
$3K |
| 86140 |
|
959 |
856 |
$3K |
| 96415 |
|
27 |
14 |
$3K |
| 84100 |
|
1,112 |
954 |
$3K |
| 80076 |
|
431 |
391 |
$2K |
| 86360 |
|
57 |
51 |
$2K |
| 82728 |
|
181 |
171 |
$2K |
| 85652 |
|
1,076 |
966 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
96 |
85 |
$2K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
14 |
12 |
$2K |
| 80069 |
|
530 |
460 |
$2K |
| 86359 |
|
57 |
51 |
$2K |
| 82550 |
|
434 |
371 |
$1K |
| 85610 |
|
743 |
593 |
$1K |
| 87040 |
|
336 |
164 |
$1K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
41 |
36 |
$1K |
| 82607 |
|
97 |
81 |
$928.15 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
39 |
37 |
$894.34 |
| 84702 |
|
84 |
70 |
$883.43 |
| 82570 |
|
333 |
301 |
$868.67 |
| 87807 |
|
81 |
80 |
$813.85 |
| 83970 |
|
65 |
65 |
$804.14 |
| 85379 |
|
100 |
90 |
$790.08 |
| 87510 |
|
42 |
40 |
$741.85 |
| 87480 |
|
42 |
40 |
$741.85 |
| 87660 |
|
42 |
40 |
$741.85 |
| 73630 |
|
15 |
14 |
$571.05 |
| 86003 |
|
299 |
26 |
$539.95 |
| 86803 |
|
39 |
37 |
$529.96 |
| 85730 |
|
149 |
123 |
$455.25 |
| 87150 |
|
14 |
12 |
$385.99 |
| 84156 |
|
239 |
221 |
$372.21 |
| 87340 |
|
39 |
37 |
$329.06 |
| 87653 |
|
12 |
12 |
$280.72 |
| 83550 |
|
44 |
36 |
$244.21 |
| 82043 |
|
55 |
51 |
$224.55 |
| 82948 |
|
113 |
57 |
$213.14 |
| 87400 |
|
12 |
12 |
$192.96 |
| 82248 |
|
100 |
88 |
$189.99 |
| 83540 |
|
44 |
36 |
$182.02 |
| 84460 |
|
111 |
87 |
$169.68 |
| 86850 |
|
26 |
25 |
$137.89 |
| 87210 |
|
19 |
12 |
$98.90 |
| 84550 |
|
53 |
52 |
$76.21 |
| 86901 |
|
26 |
25 |
$73.47 |
| 86900 |
|
26 |
25 |
$73.47 |
| 82950 |
|
14 |
13 |
$57.00 |
| 81002 |
|
16 |
15 |
$6.86 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
213 |
188 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
18 |
12 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
425 |
222 |
$0.00 |
| 96376 |
|
18 |
13 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
169 |
114 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
15 |
13 |
$0.00 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
30 |
24 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
34 |
27 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
23 |
13 |
$0.00 |
| A6209 |
Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
311 |
108 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
323 |
208 |
$0.00 |
| A6021 |
Collagen dressing, sterile, size 16 sq. in. or less, each |
27 |
13 |
$0.00 |